SCHEMBL861749

SCHEMBL861749

CC(C)(C)Cc1ccc2[nH]c(=O)c3ccccc3c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 11/20 0.59
TNKS O95271 2/20 0.51
PARP15 Q460N3 2/20 0.51
TNKS2 Q9H2K2 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
GPR3 P46089 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
BRD4 O60885 6/20 0.50
PARP14 Q460N5 1/20 0.49
PARP10 Q53GL7 1/20 0.49
PARP12 Q9H0J9 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
PARP4 Q9UKK3 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22862767 0.91 PARP1 (0.48) PARP1TNKSPARP15TNKS2KDM4E
SCHEMBL20713914 0.84 KIF11 (0.57) KDM4EMEN1ALDH1A1GPR3KMT2A
SCHEMBL23786255 0.82 MEN1 (0.58) KDM4EMEN1ALDH1A1LMNAKMT2A
SCHEMBL26171264 0.82 KDM4E (0.48) PARP1KDM4EMEN1ALDH1A1KMT2A
SCHEMBL21025331 0.81 CA12 (0.46) PARP1KDM4EMEN1ALDH1A1KMT2A
SCHEMBL23306821 0.76 KIF11 (0.55) KDM4EMEN1ALDH1A1LMNAKMT2A
SCHEMBL6405478 0.75 PARP1 (0.54) PARP1TNKSPARP15TNKS2KDM4E
SCHEMBL20713913 0.74 KIF11 (0.67) KDM4EALDH1A1GPR3HSD17B10
SCHEMBL1230435 0.74 PARP1 (1.00) PARP1TNKSPARP15TNKS2KDM4E
SCHEMBL6554308 0.74 PARP1 (0.55) PARP1TNKSPARP15TNKS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
WO-2008156879-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2008-12-24 WO disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS IK, CRY1, MAP1LC3C PARP1 77/4885TNKS 1289/4885PARP15 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.